We serve Chemical Name:N-(6-chloro-1H-benzimidazol-2-yl)acetamide CAS:35642-74-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N-(6-chloro-1H-benzimidazol-2-yl)acetamide
CAS.NO:35642-74-1
Synonyms:Acetamide,N-(5-chloro-1H-benzimidazol-2-yl)-(9CI);Acetamide,N-(6-chloro-1H-benzimidazol-2-yl);N-(5-chloro-1(3)H-benzoimidazol-2-yl)-acetamide
Molecular Formula:C9H8ClN3O
Molecular Weight:209.63200
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:57.78000
Exact Mass:209.03600
LogP:2.24770
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Acetamide,N-(5-chloro-1H-benzimidazol-2-yl)-(9CI) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(5-chloro-1(3)H-benzoimidazol-2-yl)-acetamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Acetamide,N-(5-chloro-1H-benzimidazol-2-yl)-(9CI) Use and application,Acetamide,N-(6-chloro-1H-benzimidazol-2-yl) technical grade,usp/ep/jp grade.
Related News: but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process. (+)-(1’S,2’S,3R)-3-dibenzylamino-N-methyl-N-(2′-phenyl-2′-hydroxy-1′-methylethyl)butanamide manufacturers J.P. Morgan and William Blair analysts still backed iRhythm for the long-term despite its recent challenges. William Blair analysts wrote that the company is still a leader of a cardiac monitoring market that is under 20% penetrated and valued at approximately $2 billion. methyl (E)-6-((N-((E)-4-methoxy-4-oxobut-2-en-1-yl)-4-methylphenyl)sulfonamido)hex-2-enoate suppliers The company was one of many to step into the void for needed generic medicines as chronic shortages crippled access to key drugs, specifically in the early- to mid-stages of the pandemic. That shortage actually led the FDA to thaw its relationship with compounding pharmacies — which was once particularly icy — to ramp up production. 2-Amino-7-phosphonoheptanoic acid vendor & factory.
